Description | Lancet Microbe 2022 - 3: e693–700. Ver Autores e respectivas Afiliações:
Institution of Tropical
Medicine, Antwerp, Belgium
(S Marijke Braet MSc,
M Van Dyck-Lippens BSc,
Prof L Rigouts PhD,
Prof E Hasker PhD,
B C de Jong MD); Department of
Pharmaceutical, Biomedical
and Veterinary Sciences,
University of Antwerp,
Antwerp, Belgium
(S Marijke Braet, Prof L Rigouts);
Research Foundation Flanders,
Brussels, Belgium
(S Marijke Braet); GenoScreen,
Lille, France (A Jouet PhD,
E Lenoir MSc); Sorbonne
Université, INSERM, Centre
d’Immunologie et des Maladies
Infectieuses (Prof A Aubry PhD)
and Centre National de
Référence des Mycobactéries et
de la Résistance des
mycobactéries aux
antituberculeux (Prof A Aubry),
Paris, France; Damien
Foundation, Brussels, Belgium
(Y Assoumani MD, A Baco MSc);
National Tuberculosis and
Leprosy Control Program,
Moroni, Comoros
(A Mzembaba MD); Inserm
UMR 1137 Iame, service de
mycobactériologie spécialisée
et de référence, APHP GHU
Paris Nord, Hôpital Bichat,
Paris, France
(Prof E Cambau PhD);
Laboratory of Molecular
Biology applied to
Mycobacteria, Instituto
Oswaldo Cruz, Rio de Janeiro,
Brazil (S E G Vasconcellos PhD,
P N Suffys PhD);
U1019-UMR 9017-CIIL,
Université de Lille, CNRS,
INSERM, CHU Lille, Institut
Pasteur de Lille, Center for
Infection and Immunity of
Lille, Lille, France
(Prof P Supply PhD) | en_US |
Abstract | Despite strong leprosy control measures, including effective treatment, leprosy persists in the Comoros.
As of May, 2022, no resistance to anti-leprosy drugs had been reported, but there are no nationally representative data.
Post-exposure prophylaxis (PEP) with rifampicin is offered to contacts of patients with leprosy. We aimed to conduct
a countrywide drug resistance survey and investigate whether PEP led to the emergence of drug resistance in patients
with leprosy. | en_US |